Clinical Trial Update: Effect of the Interleukin-6 Receptor Antagonist Tocilizumab in Non-ST Elevation Myocardial Infarction [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating the interleukin-6 receptor antagonist tocilizumab in patients with non-ST elevation myocardial infarction has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-st-elevation Myocardial Infarction

Drugs mentioned

• Tocilizumab (tocilizumab)

Snippet

Sponsor: Oslo University Hospital | Conditions: Non-ST Elevation Myocardial Infarction | Phase 2 | Status: COMPLETED